The insurance reimbursement process for Phesgo, a drug that was expected to benefit from the preferential drug pricing system, is making little progress. No news has been heard on its progress for 7 months.

Roche Korea’s Perjeta (pertuzumab+ trastuzumab), a subcutaneous injectable combination of the company’s Perjeta and Herceptin, passed the Health Insurance Review and Assessment Service's Cancer Disease Deliberation Committee review in August last year.

Since then, Roche has been negotiating with the National Health Insurance Service on Perjeta’s supply and quality control terms after the application was reported to the Drug Reimbursement Evaluation Committee. However, there has bee